Endotherapeutics Pty Ltd is pleased to announce that it will assume exclusive distribution of TachoSil® in Australia, effective 18 December 2025.
This change follows a planned transition of distribution from Baxter Healthcare Pty Ltd, undertaken in close coordination with Corza Medical, the manufacturer of TachoSil. All parties have worked collaboratively to ensure a smooth and seamless transition, with continuity of supply and ongoing support for Australian healthcare providers.
“Endotherapeutics is pleased to support the distribution of TachoSil® in Australia. Our focus remains on ensuring continuity of supply, maintaining the high product quality clinicians expect, and providing consistent local support to healthcare providers,.” – Adam Srejber, CEO, Endotherapeutics.
TachoSil is a well-established surgical fibrin patch trusted by medical professionals worldwide. It is a ready-to-use surgical matrix designed to support effective haemostasis during surgical procedures.
TachoSil contains fibrinogen and thrombin as active haemostatic components and is supplied in a ready-to-use sheet format. Alternative products, including Hemopatch, are not substitutes for TachoSil.
When applied directly to the bleeding surface, TachoSil forms a stable fibrin clot that adheres to tissue, supporting rapid haemostasis without the need for sutures or additional fixation.
There will be no changes to the product itself, and the same trusted TachoSil quality and specifications will continue under Endotherapeutics’ distribution.
Learn more here
